Robuta

https://pubmed.ncbi.nlm.nih.gov/27164704/
De novo GRIN1 mutations are associated with severe intellectual disability with cortical visual impairment as well as oculomotor and movement disorders being...
nmda receptorphenotypicspectrumdistinctgenetic
https://neuropinc.com/pipeline/neuropathic-pain/
NMDA receptor modulator drugs under development at NeurOp may provide a much needed, new treatment option in the relief of neuropathic pain.
nmda receptorneuropathic painmodulationtreatment
https://pubmed.ncbi.nlm.nih.gov/34044147/?utm_medium=email&_hsenc=p2ANqtz--wD6FtLKHedp0T82ZolwAvcTrQPKtNw4bsndGxw-jHqA-aq5sYlQLVM5H677gROYhjbPk6RSSTtmJ63f66b1ecT5vvaA&_hsmi=141845939&utm_content=141845939&utm_source=hs_email
Mutations in the beta-amyloid protein (APP) cause familial Alzheimer's disease. In hAPP-J20 mice expressing mutant APP, pharmacological inhibition or genetic...
tyrosine phosphatasenmda receptorpresynapticmediatedplasticity
https://pubmed.ncbi.nlm.nih.gov/31942532/
ionotropic receptorgene polymorphismglutamatenmdatype
https://elifesciences.org/articles/20502v1/peer-reviews
peer reviewin annmda receptordependentmechanism
https://www.prnewswire.com/news-releases/relmada-therapeutics-announces-notice-of-acceptance-of-key-patent-in-europe-covering-nmda-receptor-antagonist-d-methadone-for-treatment-of-psychiatric-symptoms-300579743.html
/PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system...
therapeuticsannouncesnoticeacceptancekey
https://www.mcgill.ca/channels/event/special-lecture-interaction-between-dopamine-nmda-receptor-amygdala-28496
Martina Marzia, PhD, assistant professor, Dept of Psychiatry, University of Ottawa
nmda receptorin thespeciallectureinteraction
https://pubmed.ncbi.nlm.nih.gov/17055162/?dopt=Abstract
Neurons in the latero-capsular part of the central nucleus of the amygdala (CeA), a region now called the "nociceptive amygdala", receive predominantly...
nmda receptorsynaptic plasticityin theindependentcentral
https://elifesciences.org/articles/53664v1/peer-reviews
Ketamine, an NMDA receptor antagonist and experimental model for schizophrenia, produces decision-making deficits in monkeys, which are predicted by a lowering...
peer reviewin adecision makingcircuitmechanism